Unmet need

Pancreatic Cancer

Locally advanced pancreatic cancer remains among the hardest tumors to treat.

Current outcomes

Durable local tumor control — the next challenge in pancreatic cancer

12–15months
Median overall survival in locally advanced pancreatic cancer with current chemo- and radiotherapy regimens

In locally advanced pancreatic ductal adenocarcinoma (LA-PDAC), systemic therapy does the heavy lifting — but durable control of the primary tumor remains a defining gap.

Why local control is so hard in PDAC

Pancreatic tumors resist chemo-radiotherapy for two intrinsic reasons:

Oxygen gradient within a solid tumor

Hypoxic tumor microenvironment

Low oxygen levels reduce the effectiveness of conventional radiation therapy — oxygen enhances radiation-induced DNA damage — and limit the dose that can be safely delivered without collateral damage to surrounding healthy tissue.

Sparse vascular network around a pancreatic tumor

Poor vascularization

A limited blood supply reduces the delivery and effectiveness of systemic chemotherapy, and impaired drug penetration increases treatment resistance.

Emerging KRAS inhibitors are expected to improve systemic disease control — but persistent local progression remains a major cause of morbidity and treatment failure.

Why it matters

As systemic therapies improve, durable local control becomes increasingly important.

The opportunity

Current Options

Current first-line options for locally advanced pancreatic cancer do not provide durable local control:

01

Systemic chemotherapy

  • FOLFIRINOX
  • gemcitabine / nab-paclitaxel
What it leaves open

Acts throughout the body, but delivery to the primary tumor is limited by its poor vascularization.

02

Radiotherapy

  • SBRT
  • IORT
  • IMRT
What it leaves open

Delivers dose to the tumor site, but that dose is constrained by the surrounding healthy tissue — and hypoxia reduces the effect of radiation.

03

Ablation techniques

  • RFA
  • MWA
  • IRE
What it leaves open

Physically destroys tissue within a targeted zone — coverage is defined by the geometry of the procedure itself.

This creates an opportunity for a dedicated local-control strategy that complements systemic therapy. YntraDose® is being developed to address that gap.

YntraDose® is an investigational radiotherapeutic. Its safety and performance are being evaluated in clinical development and have not been established.

Close